Combating evolution with intelligent design: the neoglycoside ACHN-490
- 6 October 2010
- journal article
- review article
- Published by Elsevier BV in Current Opinion in Microbiology
- Vol. 13 (5), 565-573
- https://doi.org/10.1016/j.mib.2010.09.004
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Synthesis and Spectrum of the Neoglycoside ACHN-490Antimicrobial Agents and Chemotherapy, 2010
- Hospital-Acquired Infections Due to Gram-Negative BacteriaNew England Journal of Medicine, 2010
- Antistaphylococcal Activity of ACHN-490 Tested Alone and in Combination with Other Agents by Time-Kill AssayAntimicrobial Agents and Chemotherapy, 2010
- The 10 × ‘20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020Clinical Infectious Diseases, 2010
- Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infectionJournal of Antimicrobial Chemotherapy, 2010
- Detection of KPC in Acinetobacter spp. in Puerto RicoAntimicrobial Agents and Chemotherapy, 2010
- ACHN-490, a Neoglycoside with Potent In Vitro Activity against Multidrug-Resistant Klebsiella pneumoniae IsolatesAntimicrobial Agents and Chemotherapy, 2009
- Molecular Characteristics of Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia in the Calgary Health Region from 2000 to 2007: Emergence of Clone ST131 as a Cause of Community-Acquired InfectionsAntimicrobial Agents and Chemotherapy, 2009
- Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernThe Lancet Infectious Diseases, 2008
- Cumulative Effects of Several Nonenzymatic Mechanisms on the Resistance of Pseudomonas aeruginosa to AminoglycosidesAntimicrobial Agents and Chemotherapy, 2007